Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2018

Open Access 01-12-2018 | Research article

(R)-α-Lipoic acid inhibits fructose-induced myoglobin fructation and the formation of advanced glycation end products (AGEs) in vitro

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Login to get access

Abstract

Background

Fructose-mediated protein glycation (fructation) has been linked to an increase in diabetic and cardiovascular complications due to over consumption of high-fructose containing diets in recent times. The objective of the present study is to evaluate the protective effect of (R)-α-lipoic acid (ALA) against fructose-induced myoglobin fructation and the formation of advanced glycation end products (AGEs) in vitro.

Methods

The anti-glycation activity of ALA was determined using the formation of AGEs fluorescence intensity, iron released from the heme moiety of myoglobin and the level of fructosamine. The fructation-induced myoglobin oxidation was examined using the level of protein carbonyl content and thiol group estimation.

Results

The results showed that co-incubation of myoglobin (1 mg/mL), fructose (1 M) and ALA (1, 2 and 4 mM) significantly inhibited the formation of AGEs during the 30 day study period. ALA markedly decreased the levels of fructosamine, which is directly associated with the reduction of AGEs formation. Furthermore, ALA significantly reduced free iron release from myoglobin which is attributed to the protection of myoglobin from fructose-induced glycation. The results also demonstrated a significant protective effect of ALA on myoglobin oxidative damages, as seen from decreased protein carbonyl content and increased protein thiols.

Conclusion

These findings provide new insights into the anti-glycation properties of ALA and emphasize that ALA supplementation is beneficial in the prevention of AGEs-mediated diabetic and cardiovascular complications.
Literature
1.
Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3–21.CrossRefPubMed
2.
3.
Monnier VM, Taniguchi N. Advanced glycation in diabetes, aging and age-related diseases: editorial and dedication. Glycoconj J. 2016;33(4):483–6.CrossRefPubMed
4.
Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011;93(4):645–58.CrossRefPubMed
5.
Ordway GA, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J Exp Biol. 2004;207:3441–6.CrossRefPubMed
6.
Chung Y, Huang S-J, Glabe A, Jue T. Implication of CO inactivation on myoglobin function. Am J Physiol Cell Physiol. 2006;290:C1616–24.CrossRefPubMed
7.
Jürgens KD, Papadopoulos S, Peters T, Gros G. Myoglobin: just an oxygen otore or also an oxygen transporter. News Physiol Sci. 2000;15:269–74.PubMed
8.
Lin PC, Kreutzer U, Jue T. Myoglobin translational diffusion in rat myocardium and its implication on intracellular oxygen transport. J Physiol. 2007;578:595–603.CrossRefPubMed
9.
Merx MW, Flögel U, Stumpe T, Gödecke A, Decking UK, Schrader J. Myoglobin facilitates oxygen diffusion. FASEB J. 2001;15(6):1077–9.PubMed
10.
11.
12.
Wunderlich C, Flogel U, Godecke A, Heger J, Schrader J. Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts. Circ Res. 2003;92(12):1352–8.CrossRefPubMed
13.
Roy A, Sen S, Chakraborti AS. In vitro nonenzymatic glycation enhances the role of myoglobin as a source of oxidative stress. Free Radic Res. 2004;38(2):139–46.CrossRefPubMed
14.
Hendgen-Cotta UB, Kelm M, Rassaf T. Myoglobin functions in the heart. Free Radic Biol Med. 2014;73:252–9.CrossRefPubMed
15.
Banerjee S, Maity S, Chakraborti AS. Methylglyoxal-induced modification causes aggregation of myoglobin. Spectrochim Acta A Mol Biomol Spectrosc. 2016;155:1–10.CrossRefPubMed
16.
Roy A, Sil R, Chakraborti AS. Non-enzymatic glycation induces structural modifications of myoglobin. Mol Cell Biochem. 2010;338(1-2):105–14.CrossRefPubMed
17.
Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German diabetes society. Diabetes Metab Res Rev. 2001;17(3):189–212.CrossRefPubMed
18.
Proske U, Morgan DL. Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications. J Physiol. 2001;537:333–45.CrossRefPubMedPubMedCentral
19.
Rumpf KW, Kaiser H, Grone HJ, Trapp VE, Meinck HM, Goebel HH, Kunze E, Kreuzer H, Scheler F. Myoglobinuric renal failure in hyperosmolar diabetic coma. Dtsch Med Wochenschr. 1981;106(22):708–11.CrossRefPubMed
20.
Nakano S, Mugikura M, Endoh M, Ogami Y, Otsuki M. Acute pancreatitis with diabetic ketoacidosis associated with hypermyoglobinemia, acute renal failure, and DIC. J Gastroenterol. 1996;31(4):623–6.CrossRefPubMed
21.
Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun. 1999;257(2):251–8.CrossRefPubMed
22.
23.
Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315–21.CrossRefPubMed
24.
Brownlee M. Lilly lecture 1993. Glycation and diabetic complications. Diabetes. 1994;43(6):836–41.CrossRefPubMed
25.
Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19(2):227–50.CrossRefPubMed
26.
Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–60.CrossRefPubMedPubMedCentral
27.
Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997;29(3):315–31.CrossRefPubMed
28.
Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic acid - biological activity and therapeutic potential. Pharmacol Rep. 2011;63(4):849–58.CrossRefPubMed
29.
Ghelani H, Razmovski-Naumovski V, Nammi S. Chronic treatment of (R)-α-lipoic acid reduces blood glucose and lipid levels in high-fat diet and low-dose streptozotocin-induced metabolic syndrome and type 2 diabetes in Sprague-Dawley rats. Pharmacol Res Perspect. 2017;5(3):e00306.CrossRefPubMedPubMedCentral
30.
Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens. 2003;16(3):173–9.CrossRefPubMed
31.
Thirunavukkarasu V, Nandhini AT, Anuradha CV. Fructose diet-induced skin collagen abnormalities are prevented by lipoic acid. Exp Diabesity Res. 2004;5(4):237–44.CrossRefPubMedPubMedCentral
32.
Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Lipoic acid improves glucose utilisation and prevents protein glycation and AGE formation. Pharmazie. 2005;60(10):772–5.PubMed
33.
Muellenbach EM, Diehl CJ, Teachey MK, Lindborg KA, Hasselwander O, Matuschek M, et al. Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats. Life Sci. 2009;84(15-16):563–8.CrossRefPubMedPubMedCentral
34.
Li XZ, Yan HD, Wang J. Extract of Ginkgo Biloba and alpha-lipoic acid attenuate advanced glycation end products accumulation and RAGE expression in diabetic nephropathy rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011;31(4):525–31.PubMed
35.
Leu JG, Lin CY, Jian JH, Shih CY, Liang YJ. Epigallocatechin-3-gallate combined with alpha lipoic acid attenuates high glucose-induced receptor for advanced glycation end products (RAGE) expression in human embryonic kidney cells. An Acad Bras Cienc. 2013;85(2):745–52.CrossRefPubMed
36.
Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, Feldman EL. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology. 2007;148(2):548–58.CrossRefPubMed
37.
Chen SA, Chen HM, Yao YD, Hung CF, Tu CS, Liang YJ. Topical treatment with anti-oxidants and au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products. Eur J Pharm Sci. 2012;47(5):875–83.CrossRefPubMed
38.
Akihiko SMY, Satoshi H, Takayuki N, Masafumi I, Seigo K, Yoshikazu Y. Anti-Glycation activity of alpha-Lipoic acid derivatives and vitamin E derivatives. Anti-Aging Med. 2013;10:42–54.
39.
Suzuki YJ, Tsuchiya M, Packer L. Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun. 1992;17(3):211–7.CrossRefPubMed
40.
Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes. 1997;46(9):1481–90.CrossRefPubMed
41.
Kowluru RA. Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions. Life Sci. 2005;76(9):1051–60.CrossRefPubMed
42.
Kunt T, Forst T, Wilhelm A, Tritschler H, Pfuetzner A, Harzer O, et al. Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin Sci (Lond). 1999;96(1):75–82.CrossRef
43.
Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, et al. Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci. 2001;14(12):1961–7.CrossRefPubMed
44.
Gasic-Milenkovic J, Loske C, Munch G. Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J Alzheimers Dis. 2003;5(1):25–30.CrossRefPubMed
45.
Yin QQ, Dong CF, Dong SQ, Dong XL, Hong Y, Hou XY, et al. AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell Mol Neurobiol. 2012;32(8):1299–309.CrossRefPubMed
46.
Wrobel K, Wrobel K, Garay-Sevilla ME, Nava LE, Malacara JM. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem. 1997;43(9):1563–9.PubMed
47.
48.
Ohkawara E, Nohara Y, Kanno Y, Suzuki H, Matsumoto G, Kinoshita T, Watanabe M. Fructosamine assay using albumin extracted from serum. Biol Pharm Bull. 2002;25(9):1121–4.CrossRefPubMed
49.
Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994;233:346–57.CrossRefPubMed
50.
51.
Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes. 2010;59(4):1038–45.CrossRefPubMedPubMedCentral
52.
Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Litchfield JE, Ahmed MU, Reddy S, et al. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant. 1996;11:41–7.CrossRefPubMed
53.
Stanhope KL, Schwarz J-M, Havel PJ. Adverse metabolic effects of dietary fructose: results from recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol. 2013;24(3):198–206.CrossRefPubMedPubMedCentral
54.
Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J. 1992;6(11):2905–14.PubMed
55.
Sakai M, Oimomi M, Kasuga M. Experimental studies on the role of fructose in the development of diabetic complications. Kobe J Med Sci. 2002;48(5-6):125–36.PubMed
56.
Suarez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J Biol Chem. 1989;264(7):3674–9.PubMed
57.
Kanatous SB, Mammen PP, Rosenberg PB, Martin CM, White MD, Dimaio JM, et al. Hypoxia reprograms calcium signaling and regulates myoglobin expression. Am J Physiol Cell Physiol. 2009;296(3):C393–402.CrossRefPubMed
58.
Dearlove RP, Greenspan P, Hartle DK, Swanson RB, Hargrove JL. Inhibition of protein glycation by extracts of culinary herbs and spices. J Med Food. 2008;11(2):275–81.CrossRefPubMed
59.
Bhattacherjee A, Chakraborti AS. Fructose-induced modifications of myoglobin: change of structure from met (Fe3+) to oxy (Fe2+) form. Int J Biol Macromol. 2011;48(1):202–9.CrossRefPubMed
60.
Banerjee S, Chakraborti AS. Structural alterations of hemoglobin and myoglobin by glyoxal: a comparative study. Int J Biol Macromol. 2014;66(0):311–8.CrossRefPubMed
61.
Banerjee S, Chakraborti A. In Vitro study on structural alteration of Myoglobin by Methylglyoxal. Protein J. 2013;32(3):216–22.CrossRefPubMed
62.
Ramkissoon JS, Mahomoodally MF, Ahmed N, Subratty AH. Antioxidant and anti-glycation activities correlates with phenolic composition of tropical medicinal herbs. Asian Pac J Trop Med. 2013;6(7):561–9.CrossRefPubMed
63.
Elosta A, Ghous T, Ahmed N. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev. 2012;8(2):92–108.CrossRefPubMed
64.
Ziegler D, Gries FA. α-Lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(2):S62–6.CrossRefPubMed
65.
Chen WL, Kang CH, Wang SG. Lee HM: alpha-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012;55(6):1824–35.CrossRefPubMed
66.
Sun LQ, Chen YY, Wang X, Li XJ, Xue B, Qu L, Zhang TT, Mu YM, Lu JM. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol. 2012;84(7):961–73.CrossRefPubMed
67.
Muellenbach EA, Diehl CJ, Teachey MK, Lindborg KA, Archuleta TL, Harrell NB, et al. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat. Metabolism. 2008;57(10):1465–72.CrossRefPubMedPubMedCentral
68.
Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res. 2013;10(3):239–45.CrossRefPubMed
69.
Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9(9):1681–8.PubMed
70.
Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative study group. Kidney Int. 1998;54(1):193–202.CrossRefPubMed
71.
Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 2005;54(3):345–50.CrossRefPubMed
72.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605.CrossRefPubMed
73.
Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–29.CrossRefPubMedPubMedCentral
74.
Sil S, Bose T, Roy D, Chakraborti AS. Protoporphyrin IX-induced structural and functional changes in human red blood cells, hemoglobin and myoglobin. J Biosci. 2004;29(3):281–91.CrossRefPubMed
75.
Wollin SD, Jones PJ. Alpha-lipoic acid and cardiovascular disease. J Nutr. 2003;133:3327–30.PubMed
76.
Koriyama Y, Nakayama Y, Matsugo S, Kato S. Protective effect of lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Brain Res. 2013;1499:145–57.CrossRefPubMed
77.
Miyata T, Kurokawa K, Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol. 2000;11(9):1744–52.PubMed
78.
Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem J. 2006;398(2):197–206.CrossRefPubMedPubMedCentral
Metadata
Title
(R)-α-Lipoic acid inhibits fructose-induced myoglobin fructation and the formation of advanced glycation end products (AGEs) in vitro
Publication date
01-12-2018
Published in
BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-017-2076-6

Other articles of this Issue 1/2018

BMC Complementary Medicine and Therapies 1/2018 Go to the issue

Research article

Species identification approach for both raw materials and end products of herbal supplements from Tinospora species

Retraction Note

Retraction Note: Optimized extraction, composition, antioxidant and antimicrobial activities of exo and intracellular polysaccharides from submerged culture of Cordyceps cicadae

Research article

Immune-enhancing activity of C. militaris fermented with Pediococcus pentosaceus (GRC-ON89A) in CY-induced immunosuppressed model

Research article

Bioactive components and mechanisms of Chinese poplar propolis alleviates oxidized low-density lipoprotein-induced endothelial cells injury

Research article

Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial

Research article

Phytochemical profiling and in vitro screening for anticholinesterase, antioxidant, antiglucosidase and neuroprotective effect of three traditional medicinal plants for Alzheimer’s Disease and Diabetes Mellitus dual therapy